Haemostasis and Transfusion Therapy (HLS187)

This content has moved!

Haemostasis and Transfusion Therapy has moved to a new location. Please click the button below and update your bookmarks!


Haemostasis and Transfusion Therapy (HLS187)

Module Objective

By the end of the training period with respect to haemostasis and transfusion therapy ,the trainee will be able to:

  • analyse, synthesise, critically evaluate and apply knowledge
  • perform, adapt and master a range of technical and clinical skills and procedures
  • demonstrate the attitudes and behaviours necessary for professional practice as a consultant clinical scientist dealing with the complexities, uncertainties and tensions of professional practice at this level

By the end of the training period the trainee will be able to demonstrate the ability to analyse, critically evaluate and synthesise relevant knowledge and its application to their professional practice in relation to:

  • the appropriate use of blood components and products to manage congenital and acquired disorders of haemostasis including those due to:
    • inherited coagulation factor deficiencies
    • autoimmune conditions
    • thrombotic thrombocytopenic purpura
    • heparin-induced thrombocytopenia
    • bone marrow failure and/ suppression
    • major trauma
    • surgical and obstetric bleeding
    • disseminating intravascular coagulation
  • congenital and acquired qualitative and quantitative platelet disorders
  • the pathophysiology and diagnosis of coagulation disorders
  • the indications for, and adult and paediatric doses of, components and products used to achieve / maintain haemostasis in the conditions above including:
    • platelet concentrate
    • fresh frozen plasma
    • cryoprecipitate
    • albumin
    • intravenous immunoglobulin.
    • coagulation factor concentrates
    • fibrin sealants
    • diamin-8-d arginine vasopressin (Desmopressin acetate) (DDAVP).
    • tranexamic acid and other fibrinolytic inhibitors
  • clinical contraindications / cautions for using blood components and products in specific conditions such as TTP, HIT and IgA deficiency with anti-IgA
  • the value and limitations of laboratory and ‘near patient’ tests used to monitor haemostasis and guide transfusion support

At the end of the training period the trainee will be able to demonstrate a critical understanding of current relevant research, theory and knowledge and its application to the performance, adaptation and mastery of a range of technical procedures and laboratory skills and will be able to:

  • interpret laboratory results in relation to the investigations into cases of disorders of haemostasis

By the end of the training period with respect to haemostasis and transfusion therapy, trainees will be able to perform, adapt and master the clinical skills necessary to:

  • provide expert advice on the use of blood components and products for the treatment of disorders of haemostasis